Vermillion, a molecular diagnostics company, has reported positive results from the intended use study for its peripheral artery disease (PAD) blood test, Vasclir.

The prospective double-blinded multicentre study enrolled about 1,000 subjects who met specific inclusion criteria for being at increased risk of having PAD, including smokers and diabetics aged 50 or above and the elderly aged 70 or above.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The aim of the study is to develop and validate a biomarker panel applicable to the intended use population.

The individual biomarkers beta 2 microglobulin (b2m), cystatin C and hsCRP has significantly different levels between PAD subjects and non-PAD subjects.

In the previous study, these biomarkers showed correlation to the ankle-brachial index (ABI).

 

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact